HBV受体及进入抑制剂的研究进展

钠离子／牛磺胆酸共转运多肽（NTCP）是HBV感染的受体。HBV受体的发现为抗HBV新药研发提供了新靶标。阐述了HBV感染研究中遇到的瓶颈、NCTP的发现意义及其表达调节，通过近2年来的研究，发现许多药物可以阻断NTCP的受体功能，进而高效阻断HBV感染，认为HBV进入抑制剂已成为抗HBV新药研发的主流，并且有可能成为未来根治慢性乙型肝炎的策略之一。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 31; no. 4; pp. 607 - 610
Main Author 李强 卓其斌 黄玉仙 陈良
Format Journal Article
LanguageChinese
Published 复旦大学附属公共卫生临床中心 肝炎一科,上海,201508 2015
Subjects
乙型
有机阴离子转运子
综述
肝炎病毒
进入抑制剂
钠依赖
entry inhibitor
hepatitis B virus
review
有机阴离子转运子,钠依赖
进入抑制剂
organic anion transporters,sodium-dependent
综述
肝炎病毒,乙型
Online AccessGet full text

Cover

More Information
Summary:钠离子／牛磺胆酸共转运多肽（NTCP）是HBV感染的受体。HBV受体的发现为抗HBV新药研发提供了新靶标。阐述了HBV感染研究中遇到的瓶颈、NCTP的发现意义及其表达调节，通过近2年来的研究，发现许多药物可以阻断NTCP的受体功能，进而高效阻断HBV感染，认为HBV进入抑制剂已成为抗HBV新药研发的主流，并且有可能成为未来根治慢性乙型肝炎的策略之一。
Bibliography:hepatitis B virus; organic anion transporters,sodium-dependent; entry inhibitor; review
LI Qiang,ZHUO Qibin,HUANG Yuxian,et al（First Department of Hepatitis, Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China）
Sodium taurocholate cotransporting polypeptide （NTCP）was identified as the receptor for hepatitis B virus （HBV）infection in 2012.The finding of HBV receptor has provided a new target for the development of new anti-HBV drugs.This article describes the bottle-neck of research on HBV infection,as well as the significance of the finding of HBV and its expression regulation.Over the past two years, studies have shown that a variety of agents can block the receptor function of NTCP and then inhibit HBV entry efficiently.The inhibitors of HBV entry have become a major concept in the development of new anti-HBV drugs and may be one of future strategies for radical treatment of chronic hepatitis B.
22-1108/R
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2015.04.032